Our results suggest that high ENT2 expression is not related to enhanced resistance to cytarabine due to changes in drug transport, but rather it can be a paraphenomenon occurring in tumor cells, likely associated with phenotypic characteristics of higher malignancy, since this transporter facilitates the uptake of purine and pyrimidine nucleosides and nucleobases, which are required to generate new nucleotides for a very active DNA synthesis. This evidence concerns the gene SLC29A2 and neoplasm.